🔗 Share this article

Given that the United States undertakes sweeping adjustments to its immunization recommendations, a particular individual appears unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning coronavirus shots in the pandemic and has zeroed in on potential fatalities after Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Program

Agency leaders planned to announce major changes to the pediatric vaccination calendar in December, aligning the US with the Danish vaccine program, sources say – a major change that would put the US out of alignment with much of the world with no evidence for public health gain. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Høeg is set to address the audience at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this year.

A Shift at the Regulatory Body

This interim role might represent a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a greater focus upon rolling back already-approved vaccines at the FDA.

The new acting director has frequently advocated for discontinuing some childhood shot schedules in the US in order to be more like Denmark's approach, a nation with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccines – typically the purview of Dr. Prasad, head of the FDA’s vaccine center – instead of medication approval.

Questions Over Expertise

Høeg has little discernible track record in medication creation, regulation or administrative roles, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the requisite experience” for running the CDER, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a major agency. She lacks background in drug approvals.”

Past directors of CBER would “grasp legal statutes and the science of medication creation”, said a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that previous people who headed CBER have had.”

CDER has an vast portfolio at the FDA, Woodcock emphasized.

“The public just pays attention on the new drug program, but the generic drug division clears a multitude of generic medications. There’s a biosimilars program, over-the-counter program and so forth, and all of those must be managed,” Woodcock explained. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a major management element to the position, which supervises in excess of 5,000 employees. “It’s a massive management job, if you perform it correctly,” she concluded.

Agency Reaction and Contentious Policies

In response to questions about Dr. Høeg's fitness for the role and whether this assignment signifies increased cooperation among regulatory chiefs on vaccines, a spokesperson responded that the “inquiries are based on inaccurate assumptions”.

“This background matches the responsibilities of her job,” the representative stated, citing the time Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's controversial priority voucher program, a controversial one-day medication authorization process that apparently concerned her predecessors. “By what process are these therapies being selected for this fast-track system? Who is making the calls?” Howard asked. “There’s a lot of secrecy going on at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration appears to be shifting towards less stringent oversight of pharmaceuticals, aside from immunizations.”

Documented Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if problematic, track record, critics said. She authored a research paper using unverified crowd-sourced reports to estimate the incidence of myocarditis after COVID-19 immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are riskier than they are.

Part of her “policy goals” for the current government featured changing rules for recently developed shots and discontinuing “optional” immunizations, she said post-election on a podcast. At the FDA, Høeg has according to sources proposed preventing teenage boys from receiving COVID-19 vaccines.

“She is an complete true believer who begins with her conclusions and reverse-engineers to retrofit the data in a very disingenuous, untruthful way,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of fellow skeptics, {like|